BeOne Medicines AG ONC
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.50B | 6.04B | 5.66B | 5.28B | 4.92B |
| Total Other Revenue | 107.87M | 90.39M | 78.33M | 60.97M | 49.03M |
| Total Revenue | 6.61B | 6.13B | 5.74B | 5.34B | 4.97B |
| Cost of Revenue | 701.06M | 680.68M | 670.75M | 668.54M | 686.68M |
| Gross Profit | 5.91B | 5.45B | 5.07B | 4.67B | 4.29B |
| SG&A Expenses | 2.30B | 2.23B | 2.18B | 2.08B | 2.03B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.43B | 5.21B | 5.05B | 4.90B | 4.79B |
| Operating Income | 1.18B | 923.10M | 685.94M | 447.14M | 182.68M |
| Income Before Tax | 1.13B | 868.08M | 655.17M | 416.85M | 182.26M |
| Income Tax Expenses | 215.70M | 212.37M | 142.15M | 129.92M | 113.71M |
| Earnings from Continuing Operations | 915.57 | 655.71 | 513.02 | 286.93 | 68.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 915.57M | 655.71M | 513.02M | 286.93M | 68.55M |
| EBIT | 1.18B | 923.10M | 685.94M | 447.14M | 182.68M |
| EBITDA | 1.33B | 1.07B | 825.39M | 578.82M | 328.98M |
| EPS Basic | 106.05 | 76.78 | 60.49 | 34.01 | 7.62 |
| Normalized Basic EPS | 6.52 | 5.18 | 4.04 | 2.71 | 1.18 |
| EPS Diluted | 101.44 | 72.71 | 55.81 | 30.61 | 5.06 |
| Normalized Diluted EPS | 6.28 | 4.98 | 3.88 | 2.61 | 1.11 |
| Average Basic Shares Outstanding | 446.96M | 443.48M | 440.22M | 436.19M | 431.72M |
| Average Diluted Shares Outstanding | 35.71M | 35.50M | 35.25M | 34.89M | 34.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |